Journal of Vaccines & Vaccination

3^rd International Conference on Vaccines & Vaccination

July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Scientific Tracks Abstracts

• Stabilization and drying of vaccines for novel delivery

  Robert E. Sievers, Stephen P. Cape, Jessica H. Thrall, Nisha K. Shah, Scott Winston, David H. McAdams, Pankaj Pathak, Ravindra G. Muley, Vivek B. Vaidya, Rajeev M. Dhere, Diane E. Griffin, Wen-Hsuan Lin, Paul A. Rota, Mark Papania

  PDF HTML

• Adenovirus vector-induced innate-adaptive protective immunity duo against viral and bacterial infections

  De-chu C. Tang

  PDF HTML

• IL-23 encapsulated PLGA micro-particles has a strong adjuvant effect in Pertussis vaccine

  Xiao-Qing Wei

  PDF HTML

• Negative vaccination with donor splenocytes engineered with FasL as an effective mean of inducing transplantation tolerance

  Esma S. Yolcu

  PDF HTML

• Design and clinical evaluation of a novel self-adjuvanting peptide-based pan influenza A T-cell vaccine

  Campbell Bunce

  PDF HTML

• Strategies for generation of broadly cross-neutralising anti-influenza vaccine responses

  Nikolai Petrovsky

  PDF HTML

• New strategies to present an anti-candidiasis synthetic glycopeptide vaccine acceptable for human use

  Hong Xin, Jonathan Cartmell, David R. Bundle and Jim E. Cutler

  PDF HTML

• Are there time period-related differences in the prophylactic effects of bacille calmettegu?rin intravesical instillation therapy? Comparison of Japan and Western countries

  Takehiko Okamura

  PDF HTML

• Vaccine hyporesponse in healthy elderly subjects is associated with a decrease in B cell IFNα responses: Data from functional proteomic analysis using single cell network profiling

  Diane Longo, Brent Louie, Greg Friedland, Erik Evensen, Santosh Putta1, Jason Ptacek, Michelle Atallah, David Spellmeyer, Alessandra Cesano, Rachael Hawtin, Andrea Schaeffer, Suzanne Lukac, Radha Railkar, I-Ming Wang and Leon Carayannopoulos

  PDF HTML

• Applications of the vaccine ontology (vo) in vaccine data integration and computer-assisted automated reasoning

  Yongqun ?Oliver? He, Yu Lin and Zuoshuang Xiang

  PDF HTML

• Rational design of synthetic vaccine particles (SVP) for therapeutic treatment of chronic diseases

  Takashi Kei Kishimoto

  PDF HTML

• Efficacy of a mixture of synthetic peptides overlapping the conserved CBD1 epitope in gp41 of HIV-1 to protect against SHIV162P3 rectal challenge in cynomolgus macaques

  Ara Hovanessian

  PDF HTML

• Protection against influenza from innovative RNActive? technology

  Benjamin Petsch

  PDF HTML

• A novel form of 4-1BB ligand as a potent and safe adjuvant for development of therapeutic cancer vaccines

  Rajesh Kumar Sharma

  PDF HTML

• Correct L1 initiation codon generates immunologically reactive virus-like particles of a novel laboratory mouse papillomavirus (MusPV)

  A. Bennett Jenson, Joongho Joh and Shin-je Ghim

  PDF HTML

• The T-body approach combining antibody specificity with T cell activity for adoptive vaccination of cancer

  Zelig Eshhar

  PDF HTML

• Novel non-pyrogenic hydrophobized norAbuMDP and norAbuGMDP analogues for construction of proteoliposome vaccines

  Milan Raska and Jaroslav Turanek

  PDF HTML

• The pharmacodynamic study and safety evaluation on tuberculosis DNA vaccines

  Xueqiong Wu, Yan Liang and Zhongming Li

  PDF HTML

• Nanoparticles: The next generation delivery vehicle for DNA vaccines

  Muhammad Ali A. Shah and Nongyue He

  PDF HTML

• Live attenuated tetravalent dengue virus host range vaccine elicits immune response in African green monkeys

  Malcolm E. Thomas, K. M. Smith, C. M. Briggs, C. J. Spears, M. Quiles, A. Piper, M. Ribeiro, E. Huitt, D. T. Brown and R. Hernandez

  PDF HTML

• SA-4-1BBL as a novel adjuvant for the development of therapeutic vaccines

  Haval Shirwan

  PDF HTML

• Vaccination with an adenoviral vector expressing calreticulin human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

  Jorge G. Gomez-Gutierrez

  PDF HTML

• Plant-derived biopharmaceuticals: Moving plant-derived antibodies and vaccines towards clinical trials

  Rainer Fischer

  PDF HTML

• Enhancing the efficacy of conventional BCG vaccine

  Zakaria Hmama

  PDF HTML

• Vaginal epithelial model for testing effectiveness of vaccines and microbicides against STIs

  Alwyn Rapose

  PDF HTML

• Potent neutralizing antibodies against CMV infection of both fibroblast and epithelial cell infection induced using a multivalent eVLP vaccine candidate

  David E. Anderson

  PDF HTML

• Intratumoral heterogeneity and identification of tumor initiating cells (tic) for cancer vaccination

  Saroj Basak

  PDF HTML

• Development of Vero cell-based influenza H5N1 vaccines

  Min Shi Lee

  PDF HTML

• Innovations in advanced cancer therapy: Therapeutic vaccines for chronic treatments

  Gisela Gonzalez

  PDF HTML

• Your vaccine is served; BON APPETIT: An oral DNA carrying nanovaccine targets APC and eradicates melanoma in mice

  Pirouz Daftarian

  PDF HTML

• Challenges and exciting solutions to downstream bioprocessing operations for the manufacturing of therapeutic vaccine candidates

  Timothy Lee

  PDF HTML

• Development of a broad spectrum vaccine against invasive meningococcal disease

  Graham Clarke

  PDF HTML

• Supra AntigenTM technology platform: Manufacturing and development of vaccines for the treatment of Alzheimer disease

  Pedro Reis, P. Donati, A. Pfeifer, and A. Muhs

  PDF HTML

• Immunization in family medicine-Experiences from Bosnia and Herzegovina

  Obradovic Zarema and Obradovic A

  PDF HTML

• Cost-effectiveness of an additional birth dose of hepatitis B vaccine to prevent perinatal transmission in medical setting in a developing country (Mozambique)

  Vinod Mrithinjayam

  PDF HTML

• Cost of illness for cholera in a high risk urban area in Bangladesh: An analysis from the household perspective

  Abdur Razzaque Sarker, Ziaul Islam, Iqbal Ansary Khan, Amit Saha, Fahima Chowdhury, Ashraful Islam Khan, Firdausi Qadri and Jahangir A. M. Khan

  PDF HTML

• Immunological pattern of hepatitis B infection among exposed and non-exposed babies in a PMTCT program in low resource setting: Does every exposed newborn require 200 IU of hepatitis B immunoglobulin?

  Joseph Onakewhor, Charurat M, Matthew O, Esosa Osagie, Asemota and Sadoh W. E

  PDF HTML

• Incorporating of immunization course in pharmacy curriculum in Malaysia

  Omer Qutaiba B. Al-lela, Mohd. Baidi Bahari, Ramadan M. Elkalmi and Ammar Ihsan Jawad Awadh

  PDF HTML

• The observation of the immunization effect of hepatitis B vaccine to the newborn with HBeAg positive

  Zhang Ping, Lu Wei and You Wei

  PDF HTML